Tempus AI drives growth with AI-powered diagnostics and data licensing despite recent stock drop.

Tempus AI, Inc. leverages AI and a large patient database to lead in precision medicine through genomic diagnostics and data licensing. Despite a 50% decline in share price and ongoing losses, the company shows rising revenues, expanding margins, and a strong contract pipeline valued at $1.1 billion. Its net retention rate of 126% and increased 2026 revenue guidance to around $1.6 billion highlight its growth potential. These factors support a strong buy rating for long-term investors focused on transformative healthcare technology.